Latest news
Loading news…
Innocrin Pharmaceuticals
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Durham, North Carolina, United States Founded 2004 11-50 employees For Profit
Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
2
Patents
2
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 16
- Active products
- 4
- Patents granted
- 2
- Trademarks
- 0
- Top patent class
- Organic Chemistry
Company Info
- Founded
- 2004
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 6
- HQ
- Durham, North Carolina, United States
- Region
- Research Triangle, East Coast, Southern US
Signals & Scores
- Heat score
- Low
- Growth score
- Low
- Trend (7d)
- -0.1
- Trend (30d)
- 2
- Trend (90d)
- 4.1
2
professional contacts at Innocrin Pharmaceuticals
Contact execs at Innocrin Pharmaceuticals →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Innocrin Pharmaceuticals
Loading news…
FAQs about Innocrin Pharmaceuticals
People who checked this page also checked these
Browse the full Acquirezy directory.